Nakom is the most common [1] trademark for a combination drug with levodopa + carbidopa ( INN ). This drug is also registered under the trade names Vero-Levocarbidopa, Sindopa, Sinemet, Tidomet forte, Tremonorm.
It is an anti-Parkinsonian dopaminergic drug.
General Information
To reduce side effects and enhance the therapeutic effect of L-DOPA , preparations have been developed containing L-DOPA together with inhibitors of peripheral (extracerebral) L-DOPA decarboxylation. One such inhibitor is carbidopa [hydrazinomethyldopa; 3- (3,4-dioxiphenyl) -2-hydrazino-2-methyl-propionic acid].
The combination of L-dopa with carbidopa inhibits the decomposition of L-dopa in the blood and peripheral tissues and increases the level of L-dopa in the brain tissues, where L-dopa is converted to dopamine . In this regard, it is possible to use smaller doses of L-DOPA, while the therapeutic effect is faster and the severity of side effects decreases.
Indications for use Nakoma are the same as for levodopa .
Assign Nakom inside both during and after meals. Doses are selected individually, taking into account the characteristics of the action of the main component (levodopa). Usually, they begin with 1/2 tablet 1-2 times a day; if necessary, increase the daily dose by adding 1/2 tablet every 2-3 days until the optimal effect is achieved (usually up to 3-6 tablets per day, but not more than 8 tablets per day).
Patients who have previously received L-DOPA should stop L-DOPA intake (at least 12 hours before treatment) and take L-DOPA in the first days in reduced doses (no more than 3 tablets per day). The maintenance dose for most patients is 3–6 tablets per day (no more than 8 tablets per day).
Contraindications
Precautions and contraindications for the use of Nakoma are the same as for L-DOPA (levodopa).
Notes
- ↑ As of October 2008, in accordance with the value of the Vyshkovsky index for this drug (inaccessible link) .